{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:47:24Z","timestamp":1782996444708,"version":"3.54.5"},"reference-count":23,"publisher":"Weston Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>The data for 759,880 urine specimens, collected between January 2018 and September 2024, were quantitatively measured and considered for deception and poor metabolism using the metabolic ratio (MR) of norbuprenorphine to buprenorphine. We used this urinary MR of norbuprenorphine\/buprenorphine to establish two decision limits, eg, a deception limit at log \u20131.9 (0.013), where deception is likely, and a warning limit at log \u20130.86 (0.138), where deception is less clear, and the MRs may result from either deception or extremely low metabolism. We showed that the use of MRs to set decision limits, instead of large, detected doses of the parent drug, better identifies deception in patients prescribed buprenorphine.<\/jats:p>","DOI":"10.5055\/jom.1000","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:19:27Z","timestamp":1782994767000},"page":"114-121","source":"Crossref","is-referenced-by-count":0,"title":["Use of urinary metabolic ratio to detect possible deception in patients prescribed buprenorphine"],"prefix":"10.5055","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-9703","authenticated-orcid":false,"given":"Amadeo J.","family":"Pesce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Wickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"102604","unstructured":"Drug Enforcement Administration: Buprenorphine. 2025. Available at https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/buprenorphine.pdf. Accessed August 19, 2025."},{"key":"102605","doi-asserted-by":"crossref","unstructured":"Lofwall MR, Walsh SL: A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. J Addict Med. 2014; 8(5): 315-326. DOI: 10.1097\/ADM.0000000000000045.","DOI":"10.1097\/ADM.0000000000000045"},{"key":"102606","doi-asserted-by":"crossref","unstructured":"Accurso AJ, Lee JD, McNeely J: High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. J Subst Abuse Treat. 2017; 83: 62-67. DOI: 10.1016\/j.jsat.2017.10.002.","DOI":"10.1016\/j.jsat.2017.10.002"},{"key":"102607","doi-asserted-by":"crossref","unstructured":"Donroe JH, Holt SR, O\u2019Connor PG, et al.: Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug Alcohol Depend. 2017; 180: 46-51. DOI: 10.1016\/j.drugalcdep.2017.07.040.","DOI":"10.1016\/j.drugalcdep.2017.07.040"},{"key":"102608","doi-asserted-by":"crossref","unstructured":"Suzuki J, Zinser J, Issa M, et al.: Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment. Subst Abuse. 2017; 38(4): 504-507. DOI: 10.1080\/08897077.2017.1356796.","DOI":"10.1080\/08897077.2017.1356796"},{"key":"102609","doi-asserted-by":"crossref","unstructured":"Warrington JS, Warrington GS, Francis-Fath S, et al.: Urinary buprenorphine, norbuprenorphine and naloxone concentrations and ratios: Review and potential clinical implications. J Addict Med. 2020; 14(6): e344-e349. DOI: 10.1097\/ADM.0000000000000676.","DOI":"10.1097\/ADM.0000000000000676"},{"key":"102610","doi-asserted-by":"crossref","unstructured":"Han B, Jones CM, Einstein EB, et al.: Trends in and characteristics of buprenorphine misuse among adults in the US. JAMA Netw Open. 2021; 4(10): e2129409. DOI: 10.1001\/jamanetworkopen.2021.29409.","DOI":"10.1001\/jamanetworkopen.2021.29409"},{"key":"102611","doi-asserted-by":"crossref","unstructured":"Pytell JD, Whitley P, Passik SD, et al.: Association of patients\u2019 direct addition of buprenorphine to urine drug test specimens with clinical factors in opioid use disorder. JAMA Psychiatry. 2023; 80(5): 459-467. DOI: 10.1001\/jamapsychiatry.2023.0234.","DOI":"10.1001\/jamapsychiatry.2023.0234"},{"key":"102612","doi-asserted-by":"crossref","unstructured":"Rubel SK, Eisenstat M, Wolff J, et al.: Scope of, motivations for, and outcomes associated with buprenorphine diversion in the United States: A scoping review. Subst UseMisuse. 2023; 58(5): 685-697. DOI: 10.1080\/10826084.2023.2177972.","DOI":"10.1080\/10826084.2023.2177972"},{"key":"102613","unstructured":"SAMSHA: Medical review officer guidance manual for federal workplace drug testing programs. 2017. Available at https:\/\/www.samhsa.gov\/sites\/default\/files\/workplace\/mro-guidancemanual-oct2017_2.pdf. Accessed August 19, 2025."},{"key":"102614","doi-asserted-by":"crossref","unstructured":"Pesce AJ, Cua A, Wickett E: Urinary metabolic ratio of pain management and substance abuse treatment drugs: Reference interval. J Opioid Manage. 2025; 21(7): 7-39. Available at https:\/\/wmpllc.org\/ojs\/index.php\/jom\/issue\/view\/421. Accessed November 6, 2025.","DOI":"10.5055\/jom.0904"},{"key":"102615","doi-asserted-by":"crossref","unstructured":"Chang Y, Moody DE, McCance-Katz EF: Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos Biol Fate Chem. 2006; 34(3): 440-448. DOI: 10.1124\/dmd.105.006148.","DOI":"10.1124\/dmd.105.006148"},{"key":"102616","doi-asserted-by":"crossref","unstructured":"Zhou Y, Lauschke VM: The genetic landscape of major drug metabolizing cytochrome P450 genes\u2014An updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022; 22(5-6): 284-293. DOI: 10.1038\/s41397-022-00288-2.","DOI":"10.1038\/s41397-022-00288-2"},{"key":"102617","unstructured":"Krock K, Nickley J, Tran K, et al.: Correlation of fentanyl positive drug screens with other medications in patients from pain, rehabilitation and behavioral programs. Ann Clin Lab Sci. 2020; 50(2): 260-265."},{"key":"102618","doi-asserted-by":"crossref","unstructured":"Krock K, Pesce A, Ritz D, et al.: Lower cutoffs for LC-MS\/ MS urine drug testing indicates better patient compliance. Pain Phys. 2017; 7(7): E1107-E1113.","DOI":"10.36076\/ppj\/2017.7.E1107"},{"key":"102619","unstructured":"RStudio Team: Integrated development environment for R. Boston, MA: RStudio, PBC. 2020. Available at http:\/\/www.rstudio.com. Accessed September 21, 2024."},{"key":"102620","unstructured":"RCore Team: The R project for statistical computing. 2024. Available at https:\/\/www.R-project.org\/. Accessed September 21, 2024."},{"key":"102621","unstructured":"Chan S: Chapter 4.3 cumulative distribution function. In Introduction to Probability for Data Science. Ann Arbor, MI: Michigan Publishing Services, 2021: 185-196."},{"key":"102622","doi-asserted-by":"crossref","unstructured":"Schinazi R: The cumulative distribution function. In Probability with Statistical Applications. 3rd ed. Cham: Springer Nature, 2022.","DOI":"10.1007\/978-3-030-93635-8_15"},{"key":"102623","doi-asserted-by":"crossref","unstructured":"Woodsworth G: A geochemical drainage survey and its implications for metallogenesis, Central Coast mountains, British Columbia. Econ Geol. 1971; 66(8): 1104-1120. DOI: 10.2113\/gsecongeo.66.8.1104.","DOI":"10.2113\/gsecongeo.66.8.1104"},{"key":"102624","doi-asserted-by":"crossref","unstructured":"Ligavha-Mbelengwa L, Gomo M, Lapworth DJ, et al.: Pollution source delineation of emerging organic contaminants in groundwater using cumulative distribution functions. Environ Monit Assess. 2025; 197(9): 1012. DOI: 10.1007\/s10661-025-14476-7.","DOI":"10.1007\/s10661-025-14476-7"},{"key":"102625","doi-asserted-by":"crossref","unstructured":"Furo H, Schwartz DG, Sullivan RW, et al.: Buprenorphine dosage and urine quantitative buprenorphine, norbuprenorphine, and creatinine levels in an office-based opioid treatment program. Subst Use. 2021; 15: 11782218211061749. DOI: 10.1177\/11782218211061749.","DOI":"10.1177\/11782218211061749"},{"key":"102626","doi-asserted-by":"crossref","unstructured":"Furo H, Wiegand T, Rani M, et al.: Association between buprenorphine dose and the urine \u201cnorbuprenorphine\u201d to \u201ccreatinine\u201d ratio: Revised. Subst Use. 2023; 17: 11782218231153748. DOI: 10.1177\/11782218231153748.","DOI":"10.1177\/11782218231153748"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4066\/4346","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4066\/4346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:20:23Z","timestamp":1782994823000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/4066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,28]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.1000","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}